IRX-101 for Retinal Disease

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
R. Gary Lane, II MD, San Antonio, TXRetinal DiseaseIRX-101 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests the safety and effectiveness of a new anti-VEGF injection compared to a standard one.

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Demonstrate a reduction in mean 1-hr post-injection pain scores

Demonstrate a reduction in mean 1-hr post-injection pain scores
Assessment of post-intravitreal injection eye pain
Immediately following intraviteral injection
Change in post-IVT corneal epitheliopathy as evaluated by corneal fluorescein staining scores

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

5% Povidone-iodine
1 of 2
IRX-101
1 of 2

Active Control

Experimental Treatment

240 Total Participants · 2 Treatment Groups

Primary Treatment: IRX-101 · No Placebo Group · Phase 3

IRX-101
Drug
Experimental Group · 1 Intervention: IRX-101 · Intervention Types: Drug
5% Povidone-iodine
Drug
ActiveComparator Group · 1 Intervention: Providone-Iodine · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: demonstrate a reduction in mean 1-hr post-injection pain scores

Who is running the clinical trial?

iRenix Medical, Inc.Lead Sponsor
2 Previous Clinical Trials
245 Total Patients Enrolled
Stephen Smith, MDStudy ChairFounder
3 Previous Clinical Trials
305 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are at least 18 years old and are receiving injections in your eyes for treatment.

Frequently Asked Questions

Has the Federal Drug Administration sanctioned the use of IRX-101?

"IRX-101 is perceived to be highly safe, as evidenced by its 3 score on the Power scale. This reflects multiple rounds of data that validate efficacy and safety within Phase 3 trials." - Anonymous Online Contributor

Unverified Answer

Are there any opportunities to take part in this clinical experiment currently?

"Affirmative. Documentation available on clinicaltrials.gov reveals that this study, which was advertised since February 22nd 2023, is open to enrollment. The trial necessitates the recruitment of 240 volunteers from a single site." - Anonymous Online Contributor

Unverified Answer

How many individuals are being selected to partake in this research?

"Affirmative. According to the information on clinicaltrials.gov, this medical experiment began recruiting patients on February 22nd 2023 and was recently updated March 1st 2023. It is currently looking for 240 people from a single research site." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.